1. Home
  2. KINS vs ELTX Comparison

KINS vs ELTX Comparison

Compare KINS & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

HOLD

Current Price

$14.91

Market Cap

205.7M

Sector

Finance

ML Signal

HOLD

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$11.34

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KINS
ELTX
Founded
1886
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.7M
185.4M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
KINS
ELTX
Price
$14.91
$11.34
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$18.00
AVG Volume (30 Days)
134.0K
123.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
1.18%
N/A
EPS Growth
94.59
39.29
EPS
N/A
N/A
Revenue
$214,867,301.00
$2,301,000.00
Revenue This Year
$24.23
N/A
Revenue Next Year
$18.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
38.50
N/A
52 Week Low
$13.08
$6.92
52 Week High
$19.42
$14.93

Technical Indicators

Market Signals
Indicator
KINS
ELTX
Relative Strength Index (RSI) 43.88 55.50
Support Level $14.11 $9.63
Resistance Level $15.38 $11.47
Average True Range (ATR) 0.75 0.98
MACD 0.02 0.10
Stochastic Oscillator 43.48 59.84

Price Performance

Historical Comparison
KINS
ELTX

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: